New York, US – January 26, 2021 – According to World health organization, prostate cancer is the 2nd most commonly cancer and 6th leading cause of cancer death among men worldwide, there are 1.2 million new cancer cases and 0.36 million deaths in 2018. It would grow to 1.7 million by 2030 and 2.3 million new cases and 740 000 deaths by 2040 simply due to the growth and aging of the population.
In United States, with the sound health care system, most of prostate cancer patients can afford abiraterone acetate tablets price and the latest androgen receptor inhibitor for castration-resistant prostate cancer of enzalutamide price. The 5-year survival rate for most men with local or regional prostate cancer is nearly 100%. The 10-year survival rate for local, regional, and distant prostate cancer combined is 98%.
According to the Indian Council of Medical Research, in 2018, the new cases of prostate cancer in India is 25,696 and 17,184 deaths and the 5 years prevalence is 47,558. A study from 3rd part research agency shows that prostate cancer in India are constantly and rapidly increasing and the cancer projection data shows that the number of cases will double by 2030.
In India, the prostate cancer 5-year survival rate is only 64% in 2015. A study in Mumbai shows that those patients who with enzalutamide India treatment had a 91% survival rate. It means that with proper treatment may save a life or extend the number of survival years, awareness.
Abirapro is the name of abiraterone generic approved by India government in 2018. And later in 2019 enzalutamide generic with the name of Glenza. It happened after the reform from National Rural Health Mission. The government try to address lack of medical coverage in rural areas, they try to encourage the pharmaceutical company to decreased medicine price to improving health care in India’s poorest regions. Abiraterone price in India decreased 90% after abirapro launched market and enzalutamide price in India is only 15% compare to the previous. In the past years, most Indians lack health insurance, and the out-of-pocket costs make up a large portion of the spending on medical treatment in India.
India government is doing the right things. But there remain a long wait to go, because many differences in quality between rural and urban areas as well as between public and private health care.